Security
CG Oncology, Inc. Common stock · CGON
CGONNASDAQCommon stockCurrentCIK 1991792Updated Oct 20, 2026
CGON price & chart
Loading TradingView…
NASDAQ:CGON on TradingView ↗About the company
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
In the news
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 729,913,000Source | 552,471,000Source | 1,085,655,000Source | 701,445,000Source | 564,330,000Source | 1,135,262,000Source | 728,181,000Source | 579,108,000Source | 791,592,000Source | 754,797,000Source | 199,301,000Source |
| Property, Plant and Equipment, NetUSD | 15,329,000Source | 63,000Source | 14,707,000Source | 253,000Source | 84,000Source | 15,074,000Source | 264,000Source | 77,000Source | 15,596,000Source | 272,000Source | 69,000Source |
| GoodwillUSD | 12,805,000Source | — | 10,297,000Source | 10,300,000Source | — | 10,297,000Source | — | — | 10,297,000Source | — | — |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 45,145,000Source | 43,411,000Source | 19,636,000Source | 14,624,000Source | 25,158,000Source | 33,700,000Source | 41,472,000Source | 77,468,000Source | 32,490,000Source | 257,068,000Source | 8,266,000Source |
| Inventory, NetUSD | 1,501,000Source | — | 1,003,000Source | — | — | 1,493,000Source | — | — | 1,565,000Source | — | — |
| Assets, CurrentUSD | 695,790,000Source | 552,080,000Source | 1,049,647,000Source | 673,030,000Source | 563,864,000Source | 1,102,143,000Source | 701,192,000Source | 578,610,000Source | 759,475,000Source | 754,210,000Source | 194,124,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 13,511,000Source | 11,233,000Source | 19,949,000Source | 11,416,000Source | 10,802,000Source | 23,133,000Source | 12,413,000Source | 11,949,000Source | 15,067,000Source | 11,431,000Source | 6,358,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,203,000Source | 275,000Source | 5,730,000Source | 965,000Source | 329,000Source | 4,512,000Source | 1,033,000Source | 368,000Source | 3,971,000Source | 221,000Source | 422,000Source |
| Other Assets, NoncurrentUSD | 114,000Source | 53,000Source | 4,729,000Source | 522,000Source | 53,000Source | 2,676,000Source | 516,000Source | 53,000Source | 1,678,000Source | 94,000Source | 19,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 42,270,000Source | 15,701,000Source | 56,537,000Source | 31,087,000Source | 11,971,000Source | 43,483,000Source | 23,423,000Source | 10,168,000Source | 38,990,000Source | 21,420,000Source | 14,511,000Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 8,000Source | 7,000Source | 9,000Source | 8,000Source | 7,000Source | 9,000Source | 8,000Source | 7,000Source | 8,000Source | 8,000Source | — |
| Additional Paid in CapitalUSD | 1,025,302,000Source | 722,946,000Source | 1,547,343,000Source | 964,209,000Source | 718,130,000Source | 1,530,948,000Source | 957,183,000Source | 715,807,000Source | 1,131,570,000Source | 951,350,000Source | 6,842,000Source |
| Retained Earnings (Accumulated Deficit)USD | -337,667,000Source | -186,183,000Source | -518,234,000Source | -293,859,000Source | -165,778,000Source | -439,178,000Source | -252,433,000Source | -146,874,000Source | -378,976,000Source | -217,981,000Source | -129,942,000Source |
| Stockholders' Equity Attributable to ParentUSD | 687,643,000Source | 536,770,000Source | 1,029,118,000Source | 670,358,000Source | 552,359,000Source | 1,091,779,000Source | 704,758,000Source | 568,938,000Source | 752,602,000Source | 733,377,000Source | -123,100,000Source |
| Liabilities and EquityUSD | 729,913,000Source | 552,471,000Source | 1,085,655,000Source | 701,445,000Source | 564,330,000Source | 1,135,262,000Source | 728,181,000Source | 579,108,000Source | 791,592,000Source | 754,797,000Source | 199,301,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 30,528,000Source | 15,630,000Source | 47,240,000Source | 30,381,000Source | 11,853,000Source | 35,216,000Source | 22,642,000Source | 9,984,000Source | 30,836,000Source | 21,368,000Source | 14,254,000Source |
| Operating Lease, Liability, CurrentUSD | 912,000Source | 225,000Source | 985,000Source | 288,000Source | 237,000Source | 1,066,000Source | 255,000Source | 220,000Source | 915,000Source | 186,000Source | 217,000Source |
| Accounts Payable, CurrentUSD | 9,193,000Source | 4,076,000Source | 12,727,000Source | 7,125,000Source | 4,491,000Source | 8,236,000Source | 6,731,000Source | 4,658,000Source | 5,714,000Source | 6,517,000Source | 3,242,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,329,000Source | 71,000Source | 4,834,000Source | 706,000Source | 118,000Source | 3,509,000Source | 781,000Source | 184,000Source | 3,106,000Source | 52,000Source | 244,000Source |
| Other Liabilities, NoncurrentUSD | 3,804,000Source | — | 1,156,000Source | — | — | 1,451,000Source | — | — | 1,741,000Source | — | — |
| Additional Financial Items | |||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 30,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 3,000,000Source | — | 3,000,000Source | — | — | 3,000,000Source | — | — | 3,000,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -60,202,000Source | -34,452,000Source | -160,995,000Source | -88,039,000Source | -48,607,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 841,000Source | 24,000Source | 1,445,000Source | 32,000Source | 17,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,474,000Source | 5,151,000Source | 26,676,000Source | 11,402,000Source | 1,528,000Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 587,000Source | — | 320,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -72,000Source | — | 444,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,522,000Source | 214,000Source | -1,644,000Source | 3,275,000Source | 2,012,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -278,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -56,943,000Source | -29,277,000Source | -132,346,000Source | -78,713,000Source | -45,679,000Source |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 21,967,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -334,845,000Source | -186,769,000Source | -245,822,000Source | -300,764,000Source | -121,195,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 304,000Source | 16,000Source | 134,000Source | 234,000Source | — |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 392,998,000Source | 450,000Source | 153,590,000Source | 628,279,000Source | 86,997,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,210,000Source | -215,596,000Source | -224,578,000Source | 248,802,000Source | -79,877,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 45,145,000Source | 43,411,000Source | 19,636,000Source | 14,624,000Source | 33,700,000Source | 41,472,000Source | 32,490,000Source | 257,068,000Source | 8,266,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 47,000Source | — | 103,000Source | — | 376,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 16,000Source | — | — |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,331,000Source | 2,649,000Source | 14,334,000Source | 7,007,000Source | 6,474,000Source | 5,151,000Source | 26,676,000Source | 11,402,000Source | 1,528,000Source |
| DepreciationUSD | — | — | 500,000Source | — | — | — | 800,000Source | — | 1,400,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 23,334,000Source | 8,716,000Source | 28,976,000Source | 17,410,000Source | 20,780,000Source | 14,789,000Source | 73,526,000Source | 33,703,000Source | 9,901,000Source |
| GoodwillUSD | — | — | 12,805,000Source | — | 10,297,000Source | 10,300,000Source | 10,297,000Source | — | 10,297,000Source | — | — |
| Goodwill, Impairment LossUSD | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -270,000Source | — | — |
| Investment Income, InterestUSD | — | — | 7,421,000Source | 7,892,000Source | 7,329,000Source | 7,319,000Source | 6,288,000Source | 7,747,000Source | 29,931,000Source | 26,624,000Source | 6,904,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -43,808,000Source | -20,405,000Source | -79,056,000Source | -41,426,000Source | -60,202,000Source | -34,452,000Source | -160,995,000Source | -88,039,000Source | -48,607,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -20,405,000Source | — | — | — | — | -160,995,000Source | -88,039,000Source | -67,798,000Source |
| Nonoperating Income (Expense)USD | — | — | 7,321,000Source | 7,890,000Source | 7,345,000Source | 7,315,000Source | 6,187,000Source | 7,752,000Source | 29,779,000Source | 26,627,000Source | 6,842,000Source |
| Operating Costs and ExpensesUSD | — | — | 52,795,000Source | 28,338,000Source | 87,558,000Source | 48,741,000Source | 67,472,000Source | 42,256,000Source | 194,814,000Source | — | — |
| Operating ExpensesUSD | — | — | — | 28,338,000Source | — | 48,741,000Source | — | 42,256,000Source | — | 115,805,000Source | 55,653,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -100,000Source | -2,000Source | 16,000Source | -4,000Source | -101,000Source | 5,000Source | -152,000Source | 3,000Source | -62,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 587,394,000Source | 361,892,000Source | 1,067,860,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 391,550,000Source | — | 147,450,000Source | 223,059,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,669,000Source | 682,000Source | 6,456,000Source | 2,599,000Source | 2,082,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 1,666,000Source | 43,000Source | 1,157,000Source | 0Source | 1,083,000Source | 52,000Source | 4,040,000Source | 1,139,000Source | 204,000Source |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | — | — | — | — |
| Unrealized Gain (Loss) on Investments | — | — | — | — | — | — | —Source | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -51,129,000Source | -28,295,000Source | -86,401,000Source | -48,741,000Source | -66,389,000Source | -42,204,000Source | -190,774,000Source | -114,666,000Source | -55,449,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -100,000Source | -2,000Source | 16,000Source | -4,000Source | -101,000Source | 5,000Source | -152,000Source | 3,000Source | -62,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -270,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -43,808,000Source | -20,405,000Source | -79,056,000Source | -41,426,000Source | -60,202,000Source | -34,452,000Source | -160,995,000Source | -88,039,000Source | -48,607,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.57Source | -0.3Source | -0.9Source | -0.54Source | -0.71Source | -0.45Source | -2.08Source | -1.41Source | -15.65Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.57Source | -0.3Source | -0.9Source | -0.54Source | -0.71Source | -0.45Source | -2.08Source | -1.41Source | -15.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 76,729,726Source | 67,143,744Source | 88,200,023Source | 76,226,829Source | 84,518,512Source | 76,187,621Source | 77,303,440Source | 62,496,725Source | 4,330,933Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 76,729,726Source | 67,143,744Source | 88,200,023Source | 76,226,829Source | 84,518,512Source | 76,187,621Source | 77,303,440Source | 62,496,725Source | 4,330,933Source |
| Additional Financial Items | |||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 8,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 23,334,000Source | 8,716,000Source | 28,976,000Source | 17,410,000Source | 20,780,000Source | 14,789,000Source | 73,526,000Source | 33,703,000Source | 9,901,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | — | — |
| Investment Income, InterestUSD | — | — | 7,421,000Source | 7,892,000Source | 7,329,000Source | 7,319,000Source | 6,288,000Source | 7,747,000Source | 29,931,000Source | 26,624,000Source | 6,904,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -20,405,000Source | — | — | — | — | -160,995,000Source | -88,039,000Source | -67,798,000Source |
| Nonoperating Income (Expense)USD | — | — | 7,321,000Source | 7,890,000Source | 7,345,000Source | 7,315,000Source | 6,187,000Source | 7,752,000Source | 29,779,000Source | 26,627,000Source | 6,842,000Source |
| Operating Costs and ExpensesUSD | — | — | 52,795,000Source | 28,338,000Source | 87,558,000Source | 48,741,000Source | 67,472,000Source | 42,256,000Source | 194,814,000Source | — | — |
| Operating ExpensesUSD | — | — | — | 28,338,000Source | — | 48,741,000Source | — | 42,256,000Source | — | 115,805,000Source | 55,653,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 410,000Source |
| Research and Development ExpenseUSD | — | — | 27,884,000Source | 19,622,000Source | 54,657,000Source | 31,331,000Source | 43,730,000Source | 27,467,000Source | 116,641,000Source | 82,102,000Source | 45,752,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 1,666,000Source | 43,000Source | 1,157,000Source | 0Source | 1,083,000Source | 52,000Source | 4,040,000Source | 1,139,000Source | 204,000Source |
Filing attachments
ck0001991792-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 3 ck0001991792-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term • BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026 • Phase 3 BOND-003 Cohort C Study Results published in The Lancet Oncology, further validating the strength of the…
Read attachment ↗ck0001991792-ex99_1.htm · 8-K · 2026-05-08
EX-99.1 2 ck0001991792-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates • Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026 • CORE-008 Cohort CX Phase 2 first results of combination cretostimogen…
Read attachment ↗ck0001991792-ex99_1.htm · 8-K · 2026-01-09
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., January 9, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced an expedited timeline for the to…
Read attachment ↗ck0001991792-ex99_2.htm · 8-K · 2026-01-09
Attacking Bladder Cancer for a Better Tomorrow™ Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned cli…
Read attachment ↗